Abstract:Fragile X Syndrome (FXS) is a leading inherited cause of autism and intellectual disability, resulting from a mutation in the FMR1 gene and subsequent loss of its protein product FMRP. Despite this simple genetic origin, FXS is a phenotypically complex disorder with a range of physical and neurocognitive disruptions. While numerous molecular and cellular pathways are affected by FMRP loss, there is growing evidence that circuit hyperexcitability may be a common convergence point that can account for many of the wide-ranging phenotypes seen in FXS. The mechanisms for hyperexcitability in FXS include alterations to excitatory synaptic function and connectivity, reduced inhibitory neuron activity, as well as changes to ion channel expression and conductance. However, understanding the impact of FMR1 mutation on circuit function is complicated by the inherent plasticity in neural circuits, which display an array of homeostatic mechanisms to maintain activity near set levels. FMRP is also an important regulator of activity-dependent plasticity in the brain, meaning that dysregulated plasticity can be both a cause and consequence of hyperexcitable networks in FXS. This makes it difficult to separate the direct effects of FMR1 mutation from the myriad and pleiotropic compensatory changes associated with it, both of which are likely to contribute to FXS pathophysiology. Here we will: (1) review evidence for hyperexcitability and homeostatic plasticity phenotypes in FXS models, focusing on similarities/differences across brain regions, cell-types, and developmental time points; (2) examine how excitability and plasticity disruptions interact with each other to ultimately contribute to circuit dysfunction in FXS; and (3) discuss how these synaptic and circuit deficits contribute to disease-relevant behavioral phenotypes like epilepsy and sensory hypersensitivity. Through this discussion of where the current field stands, we aim to introduce perspectives moving forward in FXS research.

Oligodendroglia and myelin pathology in fragile X syndrome

Role of fragile X messenger ribonucleoprotein 1 in the pathophysiology of brain disorders: a glia perspective

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues

Developmental Impairments of Synaptic Refinement in the Thalamus of a Mouse Model of Fragile X Syndrome

The Fragile X Messenger Ribonucleoprotein 1 regulates the morphology and maturation of human and rat oligodendrocytes

Impaired GABA Neural Circuits Are Critical for Fragile X Syndrome

Developmental studies in fragile X syndrome

New perspectives on the biology of fragile X syndrome.

Epigenetic insights into Fragile X Syndrome

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Hyperexcitability and Homeostasis in Fragile X Syndrome

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

From wings to whiskers to stem cells: why every model matters in fragile X syndrome research

Modeling Fragile X Syndrome: Characterizing Fmr1 Gene Knockout Mice across Genotype, Behavior, and Morphology

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment

Increased Coupling Of Caveolin-1 And Estrogen Receptor Alpha Contributes To The Fragile X Syndrome

Cell- and Pathway-Specific Disruptions in the Accumbens of Fragile X Mouse

Identification of Fragile X Syndrome Specific Molecular Markers in Human Fibroblasts: A Useful Model to Test the Efficacy of Therapeutic Drugs

Astrocytes regulate inhibition in Fragile X Syndrome

Modelling fragile X syndrome in the laboratory setting: A behavioral perspective

Age-Dependent Dysregulation of APP in Neuronal and Skin Cells from Fragile X Individuals